Dyne Therapeutics, Inc. (DYN)
NasdaqGS · USD · Healthcare · Biotechnology
$16.94 (+7.76%) as of
Key statistics
- Market cap
- 3.16B
- Forward P/E
- -5.08
- EPS (TTM)
- -3.30
- Dividend yield
- 0.00%
- 52-week range
- 14.00 – 27.31
- Beta
- 1.12
- Profit margin
- 0.00%
- Analyst target
- $36.00
- Volume
- 3.00M
About Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Waltham, MA, United States
- Employees
- 289
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.